Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Neuroscience CRO Services
Cyagen provides one-stop neuroscience CRO solutions from custom animal model generation to behavioral and molecular efficacy evaluation, enabling precise, rapid, and reliable preclinical research.
One-Stop Neuroscience CRO Solutions
Cyagen’s integrated neuroscience research platform provides specialized genetically engineered and induced animal models, precise drug delivery, and comprehensive behavioral, pathological, and molecular analyses. With over 2,000 validated neuroscience models and a proven track record supporting publications in top journals, we streamline your research from discovery to therapeutic validation—accelerating breakthroughs in Alzheimer’s, Parkinson’s, ALS, and other neurological disorders.
{{ item.title }}
{{static_tabs[0].title}}
Model Selection Made Simple
Base Strain
Search for Models
Search
Catalog Number Name Base Strain Research Application Action
{{ value.product_num || "--" }} {{ value.product_name || "--" }} {{ value.product_strain || "--" }}
{{v2}};
Inquire
Previous Page
Next Page
Looking for a custom disease model not listed in our database?
Our scientific team can develop or adapt models to fit your study requirements. Request a Custom Model Consultation >>
Case Studies: Proven Research Applications
● Validation of Genetically Modified Animal Models
Pathological Measurements of APP/PSEN1 Mice
Figure 1. Immunohistochemical analysis of β-Amyloid (Aβ) deposition in the hippocampus and cortex of APP/PSEN1 mice. β-Amyloid plaques were observed throughout both the hippocampus and cortex of APP/PSEN1 mice. The density of Aβ plaques increased significantly with age, highlighting progressive accumulation in the brains of these mice.
Phenotype of APP/PSEN1 Mice

Figure 2. Morris Water Maze performance in 10-Month-Old APP/PSEN1 Mice with or without donepezil treatment for 2 months.

During the learning phase, both the WT-saline and APP/PSEN1+Donepezil groups exhibited progressively shorter latencies, indicating intact spatial learning and locomotor activity. In contrast, the APP/PSEN1+Vehicle group did not show a significant reduction in latency, suggesting impaired spatial learning.

In the testing phase, the WT-saline and APP/PSEN1+Donepezil groups demonstrated significantly shorter latencies and a higher number of platform crossings compared to the APP/PSEN1+Vehicle group, further indicating improved spatial memory in the treatment groups.

● Validation of Induced Models
Phenotype of 6-OHDA induced Rats
Figure 3. Phenotype evaluation of 6-OHDA induced rats. Two weeks post-brain stereotaxic injection, apomorphine (APO, 0.5 mg/kg) was administered intraperitoneally, and rightward rotations were counted. The gait analysis, grip strip strength and rotarod were measured at specific time points:
  1. The WT group did not exhibit rightward rotation following APO administration.
  2. In PD rats, there was an increase in walking time, along with a decrease in average speed and stride length.
  3. However, these impairments were reversed after 20 days of L-DOPA administration.
  4. Compared to WT, PD rats showed reduced grip strength, which was mitigated after 25 days of L-DOPA treatment.
  5. Additionally, PD rats displayed decreased latency compared to WT, with L-DOPA administration reversing this reduction after 30 days.
Pathology Assessment of 6-OHDA-induced Rats

Figure 4. Immunofluorescence (IF) analysis of tyrosine hydroxylase expression three weeks post-6-OHDA injection. Tyrosine hydroxylase (TH) is a crucial marker of dopaminergic neurons, and the reduction in TH expression is a hallmark of the disease's progression. The 6-OHDA was injected into the left side of the brain. As a result, no TH fluorescence (red fluorescence) was detected in the left substantia nigra and striatum, while the right substantia nigra and striatum still exhibited TH fluorescence. These findings confirm the successful establishment of the PD rat model.

● Validation of HUGO-GT Models
Grip Strength and Rotarod of hMeCP2T158M Mice at 11 to 12-week-old
Figure 5. The grip strength and rotarod analysis of hMeCP2T158M mice at 11–12 weeks of age. For Grip Strength, both male and female hMeCP2T158M mice exhibited a decline in grip strength compared to WT and hMeCP2 control mice. For Rotarod, the performance revealed that female and male hMeCP2T158M homo/hemi mice exhibited reduced latency compared to WT and hMeCP2 control mice.
Gait Test of hMeCP2T158M Mice at 11 to 12-week-old

Figure 6. The stride width and stride length of hMeCP2T158M mice at 11 to 12-week-old. Both male and female hMeCP2T158M mice displayed increased hindlimb stride width and decreased stride length, indicating impaired locomotion and coordination.

Tau Expression in the Hippocampal Region of C57BL/6J, hMAPT WT, hMAPT P301L, and hMAPT P301S Mouse Strains

Figure 7. Tau expression in the hippocampal region was assessed across different mouse strains. Human tau, detected using the HT7 antibody, was observed in hMAPT WT, hMAPT P301L, and hMAPT P301S mice, but was absent in C57BL/6J mice. Consistently, hyperphosphorylated tau (AT8) was detected only in hMAPT P301L and hMAPT P301S mice, but not in hMAPT WT or C57BL/6J mice—indicating that tauopathy is associated with the P301L and P301S mutations. Neuronal nuclei were labeled with NeuN, and all nuclei were counterstained with DAPI. All mice were approximately 9 months old at the time of tissue collection.

{{static_tabs[1].title}}
Cyagen provides precise, customizable in vivo drug administration services designed specifically for neuroscience research. Our expert technical team ensures accurate and reproducible drug delivery directly to targeted brain and spinal regions, verified through rigorous imaging and protein expression analyses.
Administration Methods Include:
  • Stereotactic brain injection
  • Stereotactic brain injection
  • Intracerebroventricular (ICV) injection
  • Intravenous (tail vein) injection
  • Additional routes: Intranasal, intramuscular, subcutaneous, intraperitoneal, and more
Need Customized Administration for Your Project?
Request Customized Drug Administration >>
Case Examples:
1. Precise Brain Region Targeting (Stereotactic Injection)
  • Injected Substance: AAV9-CMV-EGFP-HGH
  • Titer: 1.98×10¹⁴ vg/mL
  • Dose: 1×10¹¹ vg/0.5μL per injection
  • Injection Coordinates: -2mm, ±1.8mm, -1.5mm
  • Validation: Clear GFP expression 4 weeks post-injection, demonstrating accuracy and successful delivery.
Figure 8. Imaging demonstrates accurate stereotactic delivery and localized expression of target protein.
2. Precise Brain Region Targeting (Stereotactic Injection)
  • Injected Substance: AAV9-CMV-EGFP-HGH / AAV9-CAG-EGFP
  • Titer & Dose: 4×10¹¹ vg (CMV); 1×10¹¹ vg (CAG)
  • Injection Site: Lumbar vertebrae L4-L5
  • Injection Coordinates: -2mm, ±1.8mm, -1.5mm
  • Validation: Robust protein expression observed at 2 weeks post-injection, confirming effective intrathecal drug delivery.
Figure 9. Clear GFP signal indicates successful intrathecal injection and target protein expression.
● Case Study 3
AAV9-CMV-EGFP-HGH
Coordinates: -2 mm, ±1.8 mm, -1.5 mm
Injection Titer: 1.98×10¹⁴ vg/mL
Dose: 1×10¹¹ vg/0.5 μL/site
Imaging Time: 4 weeks post-injection
White light imaging of brain section
(Note: Stained with Toluidine blue, only showing the injection location)
Fluorescence imaging of brain section
Figure 10. Precise injection site visualization using the brain stereotactic instrument.
● Case Study 4
Lipopolysaccharide Injection
Coordinates: +4.8 mm, ±1.8 mm, -8.0 mm
Concentration: 5 mg/mL
Dose: 4 μL/site
Imaging Time: 2 weeks post-injection
Rat brain stereotactic positioning injection schematic diagram
Observation: Rat displaying unidirectional rotational movement 14 days post-operation.
Figure 11. Significant behavioral changes observed 2 weeks post-injection.
{{static_tabs[2].title}}
Cyagen’s neuroscience CRO platform provides comprehensive and reliable evaluations covering behavioral assessments, pathology, molecular biology, and pharmacological analyses. Our internationally standardized assays enable accurate and reproducible measurement of neurological outcomes and therapeutic efficacy, supporting researchers worldwide from preclinical validation to clinical translation.
Behavioral Assays
  • Morris Water Maze
  • Y Maze
  • Rotarod
  • Open Field Test (OFT)
  • Novel Object Recognition Test (NORT)
  • Elevated Plus Maze (EPM)
  • Forced Swimming Test (FST)
  • Grip Strength Test
  • Social Interaction Tests
  • Treadmill & Balance Beam Test
  • Tail Suspension Test and more
Pathological Analysis
  • Tissue preparation and sectioning
  • H&E staining
  • Immunohistochemistry (IHC)
  • Immunofluorescence staining (IF)
  • Special staining techniques
  • Fluorescent imaging & biomarker detection
  • Apoptosis and proliferation analysis
Biochemical Analysis
  • Quantitative PCR (qPCR)
  • RT-PCR, Southern blot
  • Western blot & ELISA
  • Protein expression and localization
  • Biomarker profiling
  • Cytokine and inflammatory marker analysis
  • Primer design & RNA extraction
Need Tailored Phenotypic & Efficacy Evaluations for Your Study?
Request Custom Evaluation Services >>
● Multifunctional Neurobehavioral Assessment
Figure 12. A comprehensive panel of behavioral tests for multifunctional neurobehavioral assessment.
Our Unique Advantages
Extensive & Validated Model Library
Rapid access to over 2,000 validated neuroscience mouse models, including KO, cKO, and HUGO-GT™ humanized models—ready-to-use within 48 hours to jumpstart your research.
Precise Drug Delivery & Reliable Results
Our skilled specialists perform targeted in vivo drug administration to precise CNS regions, with rigorous validation to guarantee reproducible and accurate data.
Comprehensive & Customizable Analysis
International-standard neurobehavioral testing paired with molecular, biochemical, and pathological analyses—fully supported by senior neuroscience experts.
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Inquiry Details
Main Area of Research
Service(s) of Interest
Project Details
Contact Information
Full Name
Email
Phone Number
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research